<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01955200</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT01955200</nct_id>
  </id_info>
  <brief_title>Optimal Anti-platelet Treatment for Patients With Clopidogrel Low Response</brief_title>
  <acronym>OPTIMAL</acronym>
  <official_title>Optimal Anti-Platelet Treatment for Patients With Stent IMplantation And Clopidogrel Low Response: OPTIMAL Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine that for patients who received stent implantation
      but present low response to regular anti-platelet treatment, whether 1-month intensified
      anti-platelet treatment by replacing clopidogrel with ticagrelor (TCL) is superior to double
      dose clopidogrel or adding cilostazol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Optimal anti-Platelet Treatment for patients with stent IMplantation And clopidogrel Low
      response: OPTIMAL study

      Previous studies showed that dual anti-platelet treatment (DAPT) with aspirin and clopidogrel
      provided 20% risk reduction for cardiovascular death, myocardial infarction and stroke
      compared with aspirin alone in patients with acute coronary syndrome (ACS)1-4. However, about
      5~40% patients were reported being low response to clopidogrel, which is associated with
      higher risk of cardiovascular events5. Thus, it is of great clinical value to explore an
      intensified anti-platelet regimen to improve the inhibition of platelet function for the
      clopidogrel low responders.

      Several intensified anti-platelet protocols have been evaluated in the non-selected ACS
      patients. OASIS-7 showed that 600mg loading dose and 1-week double dose clopidogrel was
      associated with a 42% risk reduction of the definite stent thrombosis compared with regular
      DAPT6; our meta-analysis has demonstrated that cilostazol based triple anti-platelet
      treatment (TAPT) reduces the risk of late loss of minimal lumen diameter (MLD) and binary
      angiographic restenosis as well as target lesion revascularization(TLR) and target vessel
      revascularization (TVR) compared to regular DAPT in patients undergoing coronary stent
      implantation; PLATO study showed that ticagrelor (TCL) based DAPT was associated with a
      significantly lower incidence of myocardial infarction and cardiovascular death compared with
      clopidogrel based DAPT, and the difference mainly appeared in the first 30 days7. However,
      there is still no study to investigate which of the mentioned methods is the optimal one to
      improve the anti-platelet effect as well as clinical outcome for the clopidogrel low
      responders.

      The investigators hypotheses that for patients who received stent implantation but present
      clopidogrel low response, 1-month intensified anti-platelet treatment by replacing
      clopidogrel with ticagrelor (TCL) is superior to double dose clopidogrel or adding cilostazol
      regarding the inhibition of platelet aggregation in response to adenosine diphosphate (ADP).

      Inclusion criteria:

        1. Successively recruit all patients who receive stent implantation;

        2. Patient aged &gt;18 years and ≦80 years old;

        3. Signed inform consent.

      Exclusion criteria:

        1. Allergy or intolerance to ASA, clopidogrel or TCL;

        2. Subjects at a high risk of bleeding (e.g. platelet count&lt; 80*109/L, known bleeding
           diathesis , active peptic ulcer );

        3. Patients who are planning to take warfarin or drugs that potentially could interfere
           with the anti-platelet effects of ASA (e.g. non-steroidal anti-inflammatory drugs ) ,
           clopidogrel or TCL (e.g. strong CYP3A inhibitors or CYP3A inducers).

      Randomization:

      All patients take 300mg loading dose clopidogrel plus 100mg daily ASA and 75mg daily
      clopidogrel after admission. Patients are recruited after percutaneous coronary intervention
      (PCI). Light transmittancy aggregation (LTA) in response to 5μM ADP is to measured 5 days
      after taking the loading dose clopidogrel. Patients are randomized into the following 4
      groups receiving either regular DAPT or different intensified anti-platelet treatments for 1
      month if the inhibition of platelet aggregation (IPA) is no more than 60%. All patients
      return to regular DAPT (ASA 100mg daily, clopidogrel 75mg daily) for 11 month after 1-month
      intensified treatment. Patients with IPA &gt; 60% receive regular DAPT as the 5th group.

        1. Intensified anti-platelet treatment-1: ASA 100mg daily + Ticagrelor 90mg Bid

        2. Intensified anti-platelet treatment-2: ASA 100mg daily + Clopidogrel 150mg daily

        3. Intensified anti-platelet treatment-3: ASA 100mg daily + Clopidogrel 75mg daily +
           cilostazol 150mg Bid

        4. Regular DAPT (IPA≦60%): ASA 100mg daily + Clopidogrel 75mg daily

        5. Regular DAPT (IPA&gt;60%): ASA 100mg daily + Clopidogrel 75mg daily

      Sample size calculation:

      The IPA of ticagrelor in response to ADP was reported to be 88±15%, with a 5% 2-side alpha,
      30 patients in each group would offer 80% power to demonstrate that the result of ticagrelor
      is superior to any of the other groups.

      According to previous study, we assume the ratio of clopidogrel low response is 10%, then
      1200 patients is required to reach the statistical significance. To avoid some drop-out, our
      sample size is set as 1350 patients.

      Tests:

        1. ADP-induced platelet aggregation: Light transmittancy aggregation (LTA) in response to
           5μM ADP.

        2. Arachidonic acid(AA)-induced platelet aggregation: Light transmittancy aggregation (LTA)
           in response to 1mM AA.

        3. Blood sample points: baseline (5 days after taking the loading dose clopidogrel), 1month
           after randomization.

      Clinical follow-up:

      Time points: 1month, 6month, and 1year after randomization.

      Primary endpoints:

      1. Inhibition of platelet aggregation (IPA) in response to 5μM ADP determined by light
      transmittancy aggregometer (LTA) 1-month after intensified anti-platelet treatment.

      Secondary endpoints:

        1. Clinical efficacy: death, non-fatal myocardial infarction, ischemic stroke,
           revascularization, and stent thrombosis (ARC definition);

        2. Safety: minor, moderate, and major bleeding.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibition of platelet aggregation (IPA)</measure>
    <time_frame>1-month after randomization</time_frame>
    <description>Inhibition of platelet aggregation (IPA) in response to 5μM ADP measured by light transmittancy aggregometer (LTA) 1-month after randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy</measure>
    <time_frame>1-month and 1-year</time_frame>
    <description>1-month and 1-year death, non-fatal myocardial infarction, ischemic stroke, revascularization, and stent thrombosis (ARC definition)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bleeding</measure>
    <time_frame>1-month and 1-year</time_frame>
    <description>1-month and 1-year minor, moderate, and major bleeding</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">1350</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Intensified Anti-platelet Treatment-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA + ticagrelor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensified Anti-platelet Treatment-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA + double dose clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensified Anti-platelet Treatment-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA + clopidogrel + cilostazol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular DAPT (IPA≦60%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ASA + clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular DAPT (IPA&gt;60%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ASA + clopidogrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>(ASA 100mg daily + Ticagrelor 90mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.</description>
    <arm_group_label>Intensified Anti-platelet Treatment-1</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>(ASA 100mg daily + Clopidogrel 150mg daily) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.</description>
    <arm_group_label>Intensified Anti-platelet Treatment-2</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>(ASA 100mg daily + Clopidogrel 75mg daily + Cilostazol 150mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.</description>
    <arm_group_label>Intensified Anti-platelet Treatment-3</arm_group_label>
    <other_name>Peida</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.</description>
    <arm_group_label>Regular DAPT (IPA≦60%)</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.</description>
    <arm_group_label>Regular DAPT (IPA&gt;60%)</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Successively recruit all patients who receive stent implantation;

          2. Patient aged &gt;18 years and ≦80 years old;

          3. Signed inform consent.

        Exclusion Criteria:

          1. Allergy or intolerance to ASA, clopidogrel or TCL;

          2. Subjects at a high risk of bleeding (e.g. platelet count&lt; 80*109/L, known bleeding
             diathesis , active peptic ulcer );

          3. Patients who are planning to take warfarin or drugs that potentially could interfere
             with the anti-platelet effects of ASA (e.g. non-steroidal anti-inflammatory drugs ) ,
             clopidogrel or TCL (e.g. strong CYP3A inhibitors or CYP3A inducers).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunjian Li, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunjian Li, Ph.D</last_name>
    <phone>+86-25-83718836</phone>
    <phone_ext>6018</phone_ext>
    <email>lijay@njmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dingguo Zhang, Ph.D</last_name>
    <phone>+86-25-83718836</phone>
    <phone_ext>6018</phone_ext>
    <email>zhdg0223@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuming Zhang, M.D.</last_name>
      <phone>+86-25-83718836</phone>
      <phone_ext>6360</phone_ext>
      <email>jsphkj@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi Chai, M.D.</last_name>
      <phone>+86-25-83718836</phone>
      <phone_ext>6360</phone_ext>
      <email>jsphkj@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dingguo Zhang, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 Aug 16;345(7):494-502. Erratum in: N Engl J Med 2001 Nov 15;345(20):1506. N Engl J Med 2001 Dec 6;345(23):1716.</citation>
    <PMID>11519503</PMID>
  </reference>
  <reference>
    <citation>Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess. 2004 Oct;8(40):iii-iv, xv-xvi, 1-141. Review.</citation>
    <PMID>15461878</PMID>
  </reference>
  <reference>
    <citation>Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 Apr 20;354(16):1706-17. Epub 2006 Mar 12.</citation>
    <PMID>16531616</PMID>
  </reference>
  <reference>
    <citation>Kronzon I, Feit F. Clopidogrel plus aspirin was effective but increased bleeding in acute coronary syndromes without ST-segment elevation. ACP J Club. 2002 Mar-Apr;136(2):45.</citation>
    <PMID>11874270</PMID>
  </reference>
  <reference>
    <citation>De Miguel A, Ibanez B, Badimón JJ. Clinical implications of clopidogrel resistance. Thromb Haemost. 2008 Aug;100(2):196-203. Review.</citation>
    <PMID>18690337</PMID>
  </reference>
  <reference>
    <citation>Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S; CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010 Oct 9;376(9748):1233-43. doi: 10.1016/S0140-6736(10)61088-4.</citation>
    <PMID>20817281</PMID>
  </reference>
  <reference>
    <citation>Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.</citation>
    <PMID>19717846</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2013</study_first_submitted>
  <study_first_submitted_qc>October 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2013</study_first_posted>
  <last_update_submitted>March 16, 2016</last_update_submitted>
  <last_update_submitted_qc>March 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Chunjian Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Stent implantation</keyword>
  <keyword>Clopidogrel low response</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Cilostazol</keyword>
  <keyword>Clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

